CFL1 and cancer: Here, we have (1) used a genetic approach to identify CFL as a candidate target for migrastatic strategies, (2) tested for drugs affecting actin dynamics and contractility as well as the impact of concentration ranges on cell survival, stiffness, and migration in 2D and 3D models to identify cyB and cyD as candidate migrastatic drugs that suppress cancer cell migration at concentrations not causing reduced cell viability.